Arix Bioscience PLC has confirmed the timetable for the recommended all-share acquisition of its assets by RTW Biotech Opportunities Ltd (RTW Bio). The acquisition will be carried out through a scheme of reconstruction and voluntary winding-up of Arix under section 110 of the Insolvency Act 1986. The Second General Meeting is scheduled for 12 February 2024, and shareholders are reminded to complete and return the form of proxy by 8 February 2024. If the resolution is passed, the company will be placed into members' voluntary liquidation, and the assets will be transferred to a wholly-owned subsidiary of RTW Bio.
Jefferies International Limited is acting exclusively for Arix in connection with the matters set out in the announcement. The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S. Persons under the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in compliance with the applicable securities laws of each state or other jurisdiction in which the offering will be made.